Axsome Therapeutics (Axsome Therapeutics) EPS (Diluted) : $-5.20 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics EPS (Diluted)?

Axsome Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-2.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.20.

Axsome Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-2.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.20.

Axsome Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-1.17. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.16.

During the past 3 years, the average EPS without NRIGrowth Rate was -17.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -29.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Axsome Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -12.30% per year. The lowest was -102.90% per year. And the median was -30.55% per year.

Axsome Therapeutics EPS (Diluted) Historical Data

The historical data trend for Axsome Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics EPS (Diluted) Chart

Axsome Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-2.01

-2.77

-3.47

-4.60

-5.27

Axsome Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-1.41	-0.26	-1.54	-1.32	-2.08

Competitive Comparison of Axsome Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Axsome Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's PE Ratio falls into.

Axsome Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Axsome Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-239.238	-	0)	/	45.425
	=	-5.27

Axsome Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-98.651	-	0)	/	47.351
	=	-2.08

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.20

Axsome Therapeutics (NAS:AXSM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Axsome Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics (Axsome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

19X:Germany 19X:Germany

Address

22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Executives

Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs	director
Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111